Cite
HARVARD Citation
Yu, J. et al. (2022). Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials. Alzheimer's & dementia. 8 (1), p. n/a. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Yu, J. et al. (2022). Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials. Alzheimer's & dementia. 8 (1), p. n/a. [Online].